Resverlogix (RVX) Stock Price, News & Analysis

Company Overview

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Key Stats

• Today's Range: C$0.05 to C$0.05
• 50-Day Range: C$0.04 to C$0.05
• 52-Week Range: C$0.04 to C$0.10
• Volume: 135,722 shs
• Average Volume: 68,576 shs
• Market Capitalization: C$8.91 million
• P/E Ratio: N/A
• Dividend Yield: 7.02%
• Price Target: N/A
• Consensus Rating: N/A

RVX Stock Analysis - Frequently Asked Questions

How have RVX shares performed this year?

Resverlogix's stock was trading at C$0.06 at the beginning of 2025. Since then, RVX shares have decreased by 18.2% and is now trading at C$0.05.

How were Resverlogix's earnings last quarter?

Resverlogix Corp. (TSE:RVX) released its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter.

How do I buy shares of Resverlogix?

Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Resverlogix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT) and Burcon NutraScience (BU).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/13/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:RVX
• CIK: N/A
• Web: www.resverlogix.com
• Phone: +1-403-2549252
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$2.81 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 6.06%
• Return on Assets: -34.90%

Debt

• Debt-to-Equity Ratio: -10.95
• Current Ratio: 0.13
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 132.50
• Book Value: C($0.23) per share
• Price / Book: -0.19

Miscellaneous

• Outstanding Shares: 197,937,403
• Free Float: N/A
• Market Cap: C$8.91 million
• Optionable: Not Optionable
• Beta: 0.71